AKP-020: Additional Phase IIa data

Data from 9 patients in a Phase IIa trial showed that AKP-020 significantly reduced fasting plasma glucose (FPG) levels from baseline (p<0.05) and nonsignificantly reduced FPG levels vs. placebo. Seve...